144 related articles for article (PubMed ID: 24212063)
1. Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia.
Maffei R; Fiorcari S; Bulgarelli J; Rizzotto L; Martinelli S; Rigolin GM; Debbia G; Castelli I; Bonacorsi G; Santachiara R; Forconi F; Rossi D; Laurenti L; Palumbo GA; Vallisa D; Cuneo A; Gaidano G; Luppi M; Marasca R
Exp Hematol; 2014 Feb; 42(2):126-36.e1. PubMed ID: 24212063
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.
Maffei R; Colaci E; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
Crit Rev Oncol Hematol; 2016 Jan; 97():291-302. PubMed ID: 26454471
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide in the treatment of chronic lymphocytic leukemia.
Itchaki G; Brown JR
Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
[TBL] [Abstract][Full Text] [Related]
4. [Application of lenalidomide in chronic lymphocytic leukemia].
Lei W; Zhou KS; Li YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):565-8. PubMed ID: 24763044
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia.
Riches JC; Gribben JG
Curr Cancer Drug Targets; 2016; 16(8):689-700. PubMed ID: 27055579
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment.
Schulz A; Dürr C; Zenz T; Döhner H; Stilgenbauer S; Lichter P; Seiffert M
Blood; 2013 Mar; 121(13):2503-11. PubMed ID: 23349394
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide in lymphomas and chronic lymphocytic leukemia.
Wiernik PH
Expert Opin Pharmacother; 2013 Mar; 14(4):475-88. PubMed ID: 23356486
[TBL] [Abstract][Full Text] [Related]
8. Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF.
Maffei R; Martinelli S; Castelli I; Santachiara R; Zucchini P; Fontana M; Fiorcari S; Bonacorsi G; Ilariucci F; Torelli G; Marasca R
Leuk Res; 2010 Mar; 34(3):312-21. PubMed ID: 19616847
[TBL] [Abstract][Full Text] [Related]
9. Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
Giannopoulos K; Mertens D; Stilgenbauer S
Expert Opin Pharmacother; 2011 Dec; 12(18):2857-64. PubMed ID: 22098228
[TBL] [Abstract][Full Text] [Related]
10. Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.
Spina F; Rezzonico F; Farina L; Corradini P
Eur J Haematol; 2013 Apr; 90(4):340-4. PubMed ID: 23281656
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.
Awan FT; Johnson AJ; Lapalombella R; Hu W; Lucas M; Fischer B; Byrd JC
Leuk Lymphoma; 2010 Jan; 51(1):27-38. PubMed ID: 20055657
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide in the treatment of chronic lymphocytic leukemia.
Gentile M; Recchia AG; Vigna E; Mazzone C; Lucia E; Gigliotti V; Bossio S; Madeo A; Morabito L; Servillo P; Franzese S; Caruso N; De Stefano L; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Feb; 20(2):273-86. PubMed ID: 21214505
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner.
Masood A; Chitta K; Paulus A; Khan AN; Sher T; Ersing N; Miller KC; Manfredi D; Ailawadhi S; Borrelo I; Lee KP; Chanan-Khan A
Br J Haematol; 2012 Apr; 157(1):59-66. PubMed ID: 22171982
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide as first-line therapy for elderly CLL patients.
Gilbert JA
Lancet Oncol; 2013 Aug; 14(9):e345. PubMed ID: 24058966
[No Abstract] [Full Text] [Related]
15. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.
Fiorcari S; Martinelli S; Bulgarelli J; Audrito V; Zucchini P; Colaci E; Potenza L; Narni F; Luppi M; Deaglio S; Marasca R; Maffei R
Haematologica; 2015 Feb; 100(2):253-62. PubMed ID: 25398834
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide abrogates the survival effect of bone marrow stromal cells in chronic lymphocytic leukemia.
Kriston C; Hernádfői M; Plander M; Márk Á; Takács F; Czeti Á; Szalóki G; Szabó O; Matolcsy A; Barna G
Hematol Oncol; 2021 Oct; 39(4):513-520. PubMed ID: 34013974
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
18. Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide.
Srinivasan S; Schiffer CA
Leuk Res; 2009 Apr; 33(4):561-4. PubMed ID: 18676017
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
Chanan-Khan A; Miller KC; Musial L; Lawrence D; Padmanabhan S; Takeshita K; Porter CW; Goodrich DW; Bernstein ZP; Wallace P; Spaner D; Mohr A; Byrne C; Hernandez-Ilizaliturri F; Chrystal C; Starostik P; Czuczman MS
J Clin Oncol; 2006 Dec; 24(34):5343-9. PubMed ID: 17088571
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm.
Molica S
Leuk Lymphoma; 2007 May; 48(5):866-9. PubMed ID: 17487728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
